Progress to Further Commercialisation - updates

Hi all –just wanted to share with you that I have spoken to CEO Leearne Hinch today asI, like you, get a little nervous from time to time. Difficult to capture thewhole conversation but needless to say I came away from the conversationfeeling very reassured about the business and their progress to commercializingvarious products over time - see their AGM presso timeline for next milestones.We discussed RUO EXO Net and SubB2M ELLBA feasibility results are significantmilestones for the business coming in Q1 and Q2 next year. RUO EXO Net as commercializationis the next step (Q2) and SubB2M as it will de-risk the strategy (Q1). Leearnewas extremely positive about the SubB2M product for a number of reasons;one of which was that it will be able to significantly improve the accuracy ina range of tests which are currently in the market (e.g. Prostate testing). As theprostate test is already in use it will be much simpler to add B2M to this testmaking it highly accurate and ‘fast to market’. Adding SubB2M can be done to abunch of existing tests in the market – more easily (remembering nothing iseasy in the medical space). BD1 is working with Uni’s/research houses to pursuethese goals. Also the ExoNet product for exosomes is moving quickly to commercializationbut the Exo part of the NET capability is only a small part. BD1 is talking toa range of stakeholders about other opportunities from NET – beyond exosomes. LikeI said, difficult to capture the conversation but overall I am very reassuredthat we are still on track – these things just take significant amounts of timeto go from the lab to the market.